Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on CHBE. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN101392225A reveals a recombinant yeast route for high-purity (S)-CHBE, offering significant cost reduction in API manufacturing and robust supply chain scalability.
Patent CN101260415A reveals high-efficiency biocatalytic route for chiral intermediates. Offers significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN101260415A reveals biocatalytic route for chiral intermediates. Offers supply chain stability and cost efficiency for pharmaceutical manufacturing.
Patent CN105543186A enables high-purity chiral alcohol production with reduced costs and enhanced supply chain reliability for global pharmaceutical manufacturers.
Patent CN103255183B details enzymatic synthesis of S-CHBE. High purity and yield offer supply chain stability and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN103255183B details enzymatic asymmetric reduction for high-purity intermediates. Offers significant cost reduction and supply chain reliability for statin synthesis.
Patent CN103420837A reveals a cobalt-catalyzed hydroesterification route for chiral 4-chloro-3-hydroxybutyrate, offering high atom economy and supply chain reliability for pharmaceutical manufacturers.
Patent CN112680425B reveals a novel alcohol dehydrogenase mutant for producing high-purity (S)-CHBE. This biocatalytic route offers significant cost reduction and supply chain reliability for statin manufacturing.
Patent CN104651292A reveals high-purity S-CHBE synthesis via recombinant E. coli. Achieves 100% conversion and 99.4% ee for scalable pharmaceutical intermediates.
Patent CN112143688A reveals a novel recombinant E. coli strain for high-purity (S)-CHBE production, offering significant cost reduction in API manufacturing.
Patent CN101392225B details a recombinant yeast method for high-purity statin intermediates, offering significant cost reduction in API manufacturing and supply chain reliability.
Patent CN103589665A reveals a novel Rhodococcus qingshengii strain for high-purity (S)-CHBE production, offering significant cost reduction in API manufacturing.
Patent CN114807246A details high-efficiency enzymatic reduction for chiral alcohols, offering superior stereoselectivity and industrial scalability for pharmaceutical intermediates.
Patent CN1778889A details high-purity S-CHBE production via Aureobasidium pullulans. This method offers significant cost reduction and supply chain reliability for global buyers.
Patent CN103589665B reveals Rhodococcus qingshengii strain for high-purity (S)-CHBE production. Offers mild conditions and cost reduction in pharmaceutical intermediate manufacturing.
Patent CN101319236A details a green biocatalytic method for chiral alcohols using ionic liquids. Achieve high purity and cost reduction in pharma intermediate manufacturing with scalable processes.